مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

262
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

151
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

The cost‑ effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine

Pages

  0-0

Abstract

 Background: A decision analysis model was developed to assess the cost‑ effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. Materials and Methods: This is a cost‑ effectiveness analysis performed as a cross‑ sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost‑ effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis. Results: The estimated total cost of AC and PG per patient was 1565. 23 ± 765. 31 and 2099. 08 ± 926. 99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost‑ effectiveness ratio results showed AC is a dominate alternative. Conclusion: Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    JAVAN NOUGHABI, JAVAD, REZAPOUR, AZIZ, KASSANI, AZIZ, HATAM, NAHID, & AHMADLOO, NILOOFAR. (2018). The cost‑ effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), 23(6), 0-0. SID. https://sid.ir/paper/730977/en

    Vancouver: Copy

    JAVAN NOUGHABI JAVAD, REZAPOUR AZIZ, KASSANI AZIZ, HATAM NAHID, AHMADLOO NILOOFAR. The cost‑ effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS)[Internet]. 2018;23(6):0-0. Available from: https://sid.ir/paper/730977/en

    IEEE: Copy

    JAVAD JAVAN NOUGHABI, AZIZ REZAPOUR, AZIZ KASSANI, NAHID HATAM, and NILOOFAR AHMADLOO, “The cost‑ effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine,” JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), vol. 23, no. 6, pp. 0–0, 2018, [Online]. Available: https://sid.ir/paper/730977/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button